A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13 in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2016
At a glance
- Drugs Pneumococcal-15-valent-vaccine-conjugate (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck Sharp & Dohme
- 08 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 14 Oct 2015 New trial record